About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on 3D bioprinting of tissues and organs, tissue repair and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant-based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. In 2021, CollPlant entered ...

Company Overview - CollPlant Biotechnologies is a regenerative and aesthetics medicine company focused on developing technologies and products based on non-animal-derived recombinant human collagen (rhCollagen) [1][3] - The company specializes in 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics [3] Recent Developments - CollPlant will participate in the 27th Annual H.C. Wainwright Global Investment Conference on September 8th and 9th, 2025, at the Lotte New York Palace Hotel [1] - Investors can request one-on-one meetings with CollPlant representatives during the conference [2] Strategic Partnerships - In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, a subsidiary of AbbVie, which is a leader in the dermal filler market [4]

Core Viewpoint - CollPlant Biotechnologies has announced a definitive agreement for the issuance and sale of 1,200,002 ordinary shares at a price of $3.00 per share, aiming to raise approximately $3.6 million to support its business operations and R&D initiatives [1][2]. Group 1: Offering Details - The offering includes a registered direct offering and a concurrent private placement for the same number of shares at the same price [1][2]. - The warrants issued in the private placement will be exercisable immediately and have a term of three and a half years [1][2]. - The offering is expected to close around June 2, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for general corporate purposes, including collaboration with AbbVie on a dermal filler product candidate, working capital, and funding research and development programs [2]. Group 3: Company Background - CollPlant specializes in regenerative and aesthetic medicine, focusing on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics [6]. - The company’s products are based on rhCollagen, produced using proprietary plant-based genetic engineering technology [6]. - In 2021, CollPlant entered into a development and commercialization agreement for dermal and soft tissue fillers with Allergan, a subsidiary of AbbVie [7].